Should Drug Prices Be Negotiated Under Part D Of Medicare? And If So, How?

Abstract

Medicare's Part D prescription drug benefit has offered affordable coverage to millions of elderly Americans since its January 2006 implementation. A great deal of concern has been expressed about whether drugs are being purchased in a cost-effective manner. Many believe that the government should be negotiating prices with pharmaceutical manufacturers. We look at prescription drug pricing under Part D by examining the logic behind existing arrangements and by reviewing initial evidence on the behavior of prices. We make a modest proposal for how to improve purchasing of prescription drugs in Medicare.

Cite this work

No public copy is stored for this record, so only the metadata is cited.

Stored only when both papers are in the corpus — 70 citations exist upstream.

Papers that cite the same references — the relational fallback while embeddings are still backfilling.